Skip to main content
Clinical Trials/NCT06775782
NCT06775782
Recruiting
N/A

Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis: A Multi-centered, Open-label, Blind Endpoint, Randomized Controlled Trial

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country1,150 target enrollmentAugust 10, 2025

Overview

Phase
N/A
Intervention
Remote Ischemic Conditioning (RIC) treatment
Conditions
Not specified
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
1150
Locations
1
Primary Endpoint
Modified Rankin Scale (mRS) 0-1 at 90 days
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

Large Artery Atherosclerosis is one of the most prevalent causes of stroke worldwide and is associated with a high risk of disability and recurrent strokes. Remote Ischemic Conditioning (RIC) is a promising therapy, and it has been recommended for further investigation in patients with acute ischemic stroke resulting from large artery atherosclerosis. The primary objective of this study is to assess the efficacy of RIC in patients suffering from acute moderate ischemic stroke due to large artery atherosclerosis.

Detailed Description

This multi-centered, open-label, blind endpoint, randomized controlled trial aims to investigate the efficacy of RIC in patients with acute moderate ischemic stroke due to large artery atherosclerosis. A total of 1150 participants (age 18 to 85 years) within 48 hours of symptom onset of acute moderate ischemic stroke (NIHSS score 6-16, or NIHSS score 4-5 with disabling deficits) due to large artery atherosclerosis will be enrolled. Eligible patients will be randomized in a 1:1 ratio into RIC treatment plus medical management versus medical management alone after offering informed consent. The primary endpoint is excellent functional outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1, which will be evaluated by independent researchers in the blind state.

Registry
clinicaltrials.gov
Start Date
August 10, 2025
End Date
August 31, 2027
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Remote Ischemic Conditioning + Medical Management

Patients in this group will receive Remote Ischemic Conditioning plus best medical management.

Intervention: Remote Ischemic Conditioning (RIC) treatment

Remote Ischemic Conditioning + Medical Management

Patients in this group will receive Remote Ischemic Conditioning plus best medical management.

Intervention: Medical Management

Medical Management

Patients in this group will receive best medical management alone.

Intervention: Medical Management

Outcomes

Primary Outcomes

Modified Rankin Scale (mRS) 0-1 at 90 days

Time Frame: at 90 days after randomization

The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of patients who have suffered from a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms. Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead.

Secondary Outcomes

  • Modified Rankin Scale (mRS) 0-2 at 90 days(at 90 days after randomization)
  • Distribution of the Modified Rankin Scale (mRS) at 90 days(at 90 days after randomization)
  • Early neurological deterioration within 48 hours(within 48 hours after randomization)
  • Change of NIHSS scores from baseline to 12 days(at 12 days after randomization)
  • Recurrence of Ischemic stroke within 90 days(within 90 days after randomization)
  • Quality of life measured by Euro-QoL-5D-5L at 90 days(at 90 days after randomization)
  • Death due to any cause within 90 days(within 90 days after randomization)

Study Sites (1)

Loading locations...

Similar Trials